Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Afrocentric InvestmentJSE:ACT 53 Cash-to-Debt is 0.84 as of Dec. 2025, which is 121% above its 10-year median of 0.38. GuruFocus rates JSE:ACT with a GF Score™ of 53/100 and a GF Value™ of R2.02 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 671 Healthcare Providers & Services companies, Afrocentric Investment ranks better than 51.42% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Afrocentric Investment's cash to debt ratio for the quarter that ended in Dec. 2025 was 0.84.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Afrocentric Investmentcouldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Afrocentric Investment's Cash-to-Debt or its related term are showing as below:
JSE:ACT'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.16 Med: 0.38 Max: 37.38
Current: 0.84
During the past 13 years, Afrocentric Investment's highest Cash to Debt Ratio was 37.38. The lowest was 0.16. And the median was 0.38.
JSE:ACT's Cash-to-Debt is ranked better than 51.42% of 671
companies
in the Healthcare Providers & Services industry
Industry Median: 0.8
vs JSE:ACT: 0.84
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Afrocentric Investment Cash-to-Debt Related Terms
Afrocentric Investment Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Care Facilities subindustry, Afrocentric Investment's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Afrocentric Investment Cash-to-Debt vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Afrocentric Investment's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Afrocentric Investment's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Afrocentric Investment (JSE:ACT) has a Cash-to-Debt of 0.84 as of Dec. 2025. This is 121% above median its historical median of 0.38. Over the past decade, Afrocentric Investment's Cash-to-Debt has ranged from 0.16 to 37.38. According to the industry distribution chart, Afrocentric Investment ranks #326 out of 671 companies in the Healthcare Providers & Services industry, placing it in the top 48.6%.
Is Afrocentric Investment's Cash-to-Debt too high?
Afrocentric Investment's current Cash-to-Debt of 0.84 is 121% above median its 10-year median of 0.38. Over the past 10 years, this metric has ranged from a low of 0.16 to a high of 37.38. The Healthcare Providers & Services industry median Cash-to-Debt is 0.80. Afrocentric Investment's value of 0.84 is 5% above this industry median. Based on the distribution chart, Afrocentric Investment ranks #326 out of 671 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Afrocentric Investment has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Afrocentric Investment's Cash-to-Debt compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Afrocentric Investment ranks #326 out of 671 companies for Cash-to-Debt. This puts Afrocentric Investment in the upper half of its industry. The industry median Cash-to-Debt is 0.80. Afrocentric Investment's value of 0.84 is 5% above this benchmark. Historically, Afrocentric Investment's own Cash-to-Debt has ranged from 0.16 to 37.38 over the past decade. While the company's 10-year median is 0.38 vs. the industry median of 0.80, Afrocentric Investment has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Healthcare Providers & Services company?
The median Cash-to-Debt among Healthcare Providers & Services companies is 0.80, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Afrocentric Investment's current Cash-to-Debt of 0.84 is 5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Cash-to-Debt is 0.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Afrocentric Investment's current Cash-to-Debt is 0.84, which is 121% above median its own 10-year median of 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Afrocentric Investment stock overvalued right now?
Based on GuruFocus' analysis, Afrocentric Investment (JSE:ACT) is currently considered Possible Value Trap. The stock's GF Value™ is R2.02, compared to a current price of R0.70 — trading 65.3% below its estimated fair value. The current Cash-to-Debt is 0.84, which is 121% above median its 10-year median of 0.38 and 5% above the Healthcare Providers & Services industry median of 0.80. Afrocentric Investment's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Afrocentric Investment (JSE:ACT), the current Cash-to-Debt is 0.84 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Afrocentric Investment (JSE:ACT) Overvalued in 2026?
Based on GuruFocus' analysis, Afrocentric Investment stock appears to be undervalued.
The current stock price of R0.70 is trading 65.3% below its estimated GF Value™ of R2.02.
GuruFocus considers Afrocentric Investment to be Possible Value Trap.
Key valuation signals for JSE:ACT:
Cash-to-Debt: 0.84 (121% above median its 10-year median of 0.38)
GF Value™: R2.02 vs. price of R0.70 (65.3% below fair value)
Industry Position: 5% above the Healthcare Providers & Services median (#326 of 671)
No single metric tells the full story. See the JSE:ACT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Afrocentric Investment Corp Ltd is an investment holding company providing specialised services and products to the public and private healthcare sectors. It focuses on making quality healthcare accessible and affordable to members and beneficiaries, with the principal objective of ensuring the delivery of efficient health management services and the distribution of quality products. Its business segments include Healthcare SA, comprising medical scheme administration and health risk management services; Healthcare Retail, comprising pharmaceutical sales and services; Healthcare Africa, comprising healthcare services outside South Africa in Namibia and Mauritius; and IT-related services predominantly within South Africa. It operates across South Africa, Botswana, Mauritius, and Namibia.
53GF Score
Get the complete analysis for JSE:ACT
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:ACT has been successfully added to your 
